Michael B Sporn Selected Research

bardoxolone methyl

7/2015	Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
6/2014	Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.
1/2013	The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
5/2012	The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.
1/2012	CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
11/2010	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.
3/2010	Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
12/2009	Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.
9/2008	Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids.
7/2008	Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael B Sporn Research Topics

Disease

49	Neoplasms (Cancer) 01/2019 - 01/2002
18	Carcinogenesis 01/2019 - 02/2006
17	Breast Neoplasms (Breast Cancer) 01/2019 - 10/2002
16	Inflammation (Inflammations) 01/2017 - 10/2002
12	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2002
5	Carcinoma (Carcinomatosis) 10/2015 - 03/2007
5	Body Weight (Weight, Body) 11/2009 - 02/2006
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 03/2010
4	Leukemia 10/2015 - 05/2002
4	Arthritis (Polyarthritis) 03/2007 - 02/2003
3	Neoplasm Metastasis (Metastasis) 01/2017 - 03/2011
3	Ischemia 04/2015 - 07/2011
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2007 - 01/2002
2	Triple Negative Breast Neoplasms 01/2019 - 01/2014
2	Ganglion Cysts (Ganglion) 04/2015 - 07/2011
2	Hepatocellular Carcinoma (Hepatoma) 07/2014 - 03/2005
2	Reperfusion Injury 01/2014 - 07/2011
2	Prostatic Neoplasms (Prostate Cancer) 05/2013 - 09/2008
2	Acute Lung Injury 02/2013 - 11/2009
2	Pneumonia (Pneumonitis) 02/2013 - 03/2010
2	Chronic Disease (Chronic Diseases) 10/2012 - 01/2012
2	Melanoma (Melanoma, Malignant) 03/2011 - 07/2003
2	Neuroinflammatory Diseases 01/2011 - 05/2008
2	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2009 - 12/2007
2	Adenoma (Adenomas) 11/2008 - 06/2008
2	Chondrosarcoma 01/2008 - 03/2007
1	Mucositis 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Stomatitis 01/2022
1	Hepatomegaly 01/2019

Drug/Important Bio-Agent (IBA)

48	TriterpenesIBA 12/2016 - 01/2002
28	bardoxoloneIBA 12/2016 - 01/2002
23	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 12/2016 - 07/2003
19	bardoxolone methylIBA 07/2015 - 01/2002
17	AcidsIBA 02/2013 - 05/2002
11	LG 100268IBA 01/2019 - 10/2002
9	Proteins (Proteins, Gene)FDA Link 01/2018 - 04/2005
8	Pharmaceutical PreparationsIBA 01/2022 - 12/2003
8	CarcinogensIBA 01/2019 - 10/2002
7	oleananeIBA 07/2015 - 05/2007
7	Estrogen ReceptorsIBA 01/2013 - 05/2004
7	EnzymesIBA 05/2012 - 02/2004
7	EstersIBA 05/2012 - 01/2002
6	CytokinesIBA 01/2017 - 03/2010
6	vinyl carbamateIBA 01/2016 - 03/2007
6	Transcription Factors (Transcription Factor)IBA 04/2015 - 07/2006
6	imidazoleIBA 02/2013 - 02/2006
5	LG 268IBA 01/2019 - 03/2007
5	LigandsIBA 01/2019 - 06/2005
5	Selective Estrogen Receptor Modulators (SERM)IBA 10/2006 - 10/2002
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 03/2011
4	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2019 - 01/2008
4	Matrix Metalloproteinases (MMPs)IBA 01/2008 - 02/2004
4	LY 353381 (LY353381)IBA 10/2006 - 10/2002
3	Interleukin-6 (Interleukin 6)IBA 01/2017 - 07/2008
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017 - 10/2002
3	AflatoxinsIBA 07/2014 - 02/2006
3	Phosphotransferases (Kinase)IBA 09/2013 - 10/2004
3	ErbB Receptors (EGF Receptor)IBA 09/2013 - 05/2008
3	Messenger RNA (mRNA)IBA 01/2013 - 04/2005
3	Oleanolic AcidIBA 01/2011 - 02/2006
3	AntioxidantsIBA 01/2011 - 05/2008
3	AmidesIBA 01/2011 - 03/2007
3	2- cyano- 3,12- dioxooleana- 1,9(11)- dien- 28- oic acid ethyl amideIBA 11/2010 - 03/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2007 - 05/2002
3	Caspase 8 (Caspase-8)IBA 10/2007 - 05/2002
2	Bexarotene (LGD1069)FDA Link 01/2019 - 01/2019
2	Histone Deacetylase InhibitorsIBA 01/2016 - 01/2013
2	Vorinostat FDA Link 01/2016 - 01/2013
2	Retinaldehyde (Retinal)IBA 04/2015 - 07/2011
2	NF-E2-Related Factor 2IBA 04/2015 - 06/2009
2	DNA AdductsIBA 07/2014 - 02/2006
2	ProstaglandinsIBA 06/2014 - 12/2003
2	RetinoidsIBA 05/2013 - 02/2003
2	NADPH Oxidases (NAD(P)H oxidase)IBA 02/2013 - 03/2010
2	Drug CombinationsIBA 01/2013 - 10/2006
2	ChemokinesIBA 01/2013 - 05/2012
2	Heme Oxygenase-1IBA 05/2012 - 03/2007
2	Oxygen (Dioxygen)IBA 05/2012 - 11/2009
2	Cyclin D1IBA 05/2012 - 01/2012
2	Gemcitabine FDA Link 11/2010 - 03/2010
2	Synthetic DrugsIBA 11/2010 - 12/2009
2	Oxidants (Oxidizing Agents)IBA 03/2010 - 08/2009
2	NF-kappa B (NF-kB)IBA 03/2010 - 05/2002
2	AGN 194204IBA 12/2009 - 10/2007
2	Eflornithine (Ornidyl)FDA Link 11/2008 - 06/2008
2	Sulindac (Copal)FDA LinkGeneric 11/2008 - 06/2008
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 08/2008 - 07/2007
2	Biological ProductsIBA 05/2008 - 04/2006
2	Transforming Growth Factor beta (TGF-beta)IBA 04/2008 - 05/2004
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 10/2007 - 10/2004
2	CaspasesIBA 11/2004 - 01/2002
1	Keratins (Keratin)IBA 01/2022
1	AntibodiesIBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019

Therapy/Procedure

15	Chemoprevention 01/2018 - 07/2002
6	Therapeutics 01/2017 - 04/2004
5	Oral Administration 06/2014 - 11/2009
2	Drug Therapy (Chemotherapy) 08/2008 - 11/2004
1	Radiotherapy 01/2022